System: You are provided with a paragraph. Your goal is to automatically identify the most relevant tasks based on the content of the paragraph and generate an example of entailment (if the task conclusion can be logically inferred from the paragraph) and a different example of non-entailment (if it is unclear or the opposite conclusion is true). 

Step 1: Read the paragraph carefully. 
Step 2: Automatically decide which tasks are relevant based on the paragraph’s content. Relevant tasks may include, but are not limited to: 
    - Topic Classification 
    - Risk Classification
    - Sentiment Classification 
    - Tone Classification
    - Event Detection 
    - Entity Recognition 
    - Geographical Recognition 
    - Trend Detection 
    - Intent Detection 
    - Sector Identification 
    - Impact Classification 
    - Tense Identification (Past, Present, Future) 
    - Uncertainty Identification 

Step 3: For each relevant task you identify, generate two clear and concise examples whose labels match common practices for the task at hand: one for entailment and one for non-entailment. The example should speak about the text at the 3rd person. 
Step 4: Output the results in the following JSON format:

{
    'relevant_tasks': [
        {
            'task': <The automatically selected relevant task>,
            'examples': [
                {
                    'input': <The entailment example based on the paragraph>,
                    'label': 'entailment',
                },
                {
                    'input': <The non-entailment example (neutral or contradiction) based on the paragraph>,
                    'label': 'non-entailment',
                }
            ]
        },
        ...
    ]
}
User: Clinical testing is expensive and can take many years to complete, with the outcome inherently uncertain. Failure can occur at any time during the clinical trial process. Before obtaining approval from regulatory authorities for the sale of our product candidate, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidate in humans. Prior to initiating clinical trials, a sponsor must complete extensive preclinical testing of a product candidate, including, in most cases, preclinical efficacy experiments as well as IND-enabling toxicology studies. These experiments and studies may be time-consuming and expensive to complete. The necessary preclinical testing may not be completed successfully for a preclinical product candidate and a potentially promising product candidate may therefore never be tested in humans. Once it commences, clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. We may experience numerous unforeseen events during drug development that could delay or prevent our ability to receive marketing approval or commercialize our product candidate. In particular, clinical trials of our product candidate may produce inconclusive or negative results. We have limited data regarding the safety, tolerability and efficacy of GP2 administered in combination with GM-CSF. Clinical trials also require the review and oversight of an institutional review board (“IRB”). An inability or delay in obtaining IRB approval could prevent or delay the initiation and completion of clinical trials, and the FDA may decide not to consider any data or information derived from a clinical investigation not subject to initial and continuing IRB review and approval.
Assistant: